Last reviewed · How we verify
thiostrepton
thiostrepton is a drug. It is currently FDA-approved.
Thiostrepton is a natural cyclic oligopeptide antibiotic derived from certain strains of streptomycetes, such as Streptomyces azureus and Streptomyces laurentii. It is being studied in clinical trials, including NCT05278975, for the treatment of malignant pleural effusion due to advanced or metastatic solid tumors, including mesothelioma.
At a glance
| Generic name | thiostrepton |
|---|---|
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- SAP enzyme elevation
- SGPT (ALT) enzyme elevation
- Polydipsia
- Polyuria
- Vomiting
- Diarrhea
- Bloody diarrhea
Serious adverse events
- Cushing's syndrome
- Hearing loss
- Temporary hearing loss
Key clinical trials
- Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- thiostrepton CI brief — competitive landscape report
- thiostrepton updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about thiostrepton
What is thiostrepton?
What development phase is thiostrepton in?
What are the side effects of thiostrepton?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing